Report Description:

Rise in funding for genome editing, increase in the occurrence of genetic disorders, growth in the production of genetically modified crops and increase in the developments for the technology of gene editing are the factors driving the growth of gene editing industry. Another major factor expected to fuel the growth of the market includes the rising usage of CRISPR Cas9 technology. On the other hand, strict government rules and lack of awareness among the people for genetic alteration are factors hampering the growth of gene editing market globally.

The global gene editing market size accounted for USD xx Billion in 2017 and is anticipated to exhibit the growth at a CAGR of x% in terms of revenue and reach USD xx Billion by the end of forecast spell.

Global gene editing market has been segmented by different technology, applications and geography. On the basis of technology, market is divided into Clustered regularly interspaced short palindromic repeats (CRISPR), Transcriptor-activator like effector nuclease (TALEN), Zinc Finger Nucleases (ZFN) and other techniques of gene modification (piggyback transposon, Recombinant adeno-associated virus (rAAV), megatales). Based on application, gene editing market is divided into scientific research, biotechnology, agriculture, drug discovery & development and genetic engineering.

On considering the technology, CRISPR/Cas9 segment registered for xx.x% in 2017 and is anticipated to display the trends of growth during the forecast period. In addition, initiatives of government and rise in the funding for research in the development of drugs and vaccines will augment the demand for CRISPR/Cas9 technology encouraging the growth of gene editing market.

On the basis of application, animal genetic engineering sector was accounted at USD xxx.x Million in 2017 and size of revenue size can be related to the large use of gene editing in adapting the sequence of animals genome. Increase in the consumption of dairy and other products achieved from domestic animals has driven the demand for the technique of gene editing. First choice for developed therapies of gene editing for tracking the amount produced from domestic animals will increase the growth of gene editing market over the forecast period.

Geographical segmentation of the market divides the market by several key regions covering are Asia Pacific, North America, Europe, Latin America and Middle East & Africa. The market of North America is expected to dominate the gene editing market with the highest share owing to the acceptance of advanced techniques in research institutes established in United States. Moreover, genetic illnesses such as cystic fibrosis take place at incidence of 1 in 3,000 birth in US.

Asia Pacific is expected to grow at a rapid pace in upcoming years because of the rising population and advancements in the biotechnology sector. On the other hand, Middle East & Africa clasps the minimum share of global gene editing market because of the less availability of the facilities of biotechnology.

Key players operating in the global gene editing market include Crispr therapeutics, Cellectics, Sangamo Biosciences, Editas Medicine, Thermo Fischer and more. Thermo Fischer Scientific Inc. is American International Biotechnology Company established in 2006 on collaboration of Fischer Scientific and Thermo Electronic. In the year 2014, Thermo Fischer Scientific Company declared the procurement of Life Technology Corp for USD xx.xx Billion. Life Technology Corp is the prominent player in precision laboratory and genetic testing equipment. Acquisition is helpful for the company to generate incomparable mechanism in life sciences, research, applied and specialty diagnostics market.

Global Gene Editing Market-An Overview

The evolution of the new as well as innovative technologies related to gene-editing is intensely transmuting industrial biotechnology, human therapeutics and agriculture. Moreover, developments in CRISPR (clustered regularly interspaced short palindromic repeats) has made a fecund atmosphere for the manufacturing of cost-effective products at a large scale that ranges right from the research at elementary level to the development of translational medicine. In a recent study, patent landscape of the gene-editing tools was comprehensively analyzed and concluded that CRISPR has established dominance in comparison to the preceding gene-editing technologies. Though, several gene-editing tools pioneered from the industry, CRISPR was founded by the academic research institutions. Moreover, spinout of CRISPR biotechnology establishments from the academic institutions exhibits a slight swift in business policies that were formerly controlled by the diligence. Further, these academic institutions along with their ensuing companies are contending for generating widespread rational portfolios of property in order to swiftly commercialize the products of CRISPR. Furthermore, it was found that the beginning of CRISPR has led to a fivefold growth in the investment of genome-editing bio enterprise since past one year. This ground-breaking association has impelled the global revolution of biotechnology towards the recognition of innovative gene-editing technologies. Besides, this swift is anticipated to record a continuous growth owing to the rising demand for genetically modified crops, initialed medicine and organically sustainable biofuels. On the other hand, there are certain factors that will probably restraint the market growth, like domination of academic property, negative perception among the people about genetic engineering as well as indefinite regulatory policies.

Ethical Implications of Gene Editing

Over the period of next few decades, the technologies related to genome-editing is expected to play a very significant role in terms of human as well as animal health. Presently, a number of genetically engineered strategies of therapeutic other than those from CRISPR has been used in the clinical trials of oncology are on the way of receiving the regulatory authorization. However, it is predictable that a new cohort of therapeutics will ascend, with help of CRISPR technology, because it will allow the analysts to target at the exact genome sequences. This is not possible by other therapeutic modalities. Moreover, genome-editing technologies will mostly benefit the genetic diseases; on the other hand, several non-hereditary pathologies, for instance certain degenerative sicknesses will be obstructed, since many of these sicknesses consists of growing components of genetic mutational because of the epigenetic changes.

Some challenges continue to stay in the application of CRISPR, before they are directed towards the medical ground, for instance, long lasting safety concerns, inaccurate mutations as well as deadly implications.

The Ongoing Ethical debate

The debate over the genome editing has now been extended to the international level. The clinical recognition of gene-editing tools, including CRISPR, has fostered the ethical as well as legal distresses. Moreover, the misapplication and ethical consequences of the technology over reformed germlines of humans was freshly debated at the International Summit on Human Gene Editing.

Various scientists are encouraging the prohibition or ban for gene editing. Many of the Chinese researchers have worked on the CRISPR editing on monkeys in the year 2014, where CRISPR technology was used for creating the world’s first gene-edited human embryos in 2015 and then in year 2017 used viable human embryos for developing into babies. In the year 2018, in China, He Jiankui, a Chinese researcher of biophysics from the Department of Biology, Southern University of Science and Technology have given birth to discussions and new controversies do not appear to differ easily. He Jiankui states that gene editing was done in the laboratory which results in twin baby girls named Nana and Lulu, where He Jiankui also states that genetic modification will have the potential to attack any infection of human immunodeficiency virus (HIV) in future. Technology of gene editing named CRISPR is used for modifying the DNA during the in-vitro fertilization, whereas university proves to have no participation in the experiment of gene editing in humans. This research has produced pressure on companies tangled in gene editing and not able to find the subjects for carrying the clinical trials, results in the hampering the invention and is the main restraint for the growth of gene editing market.